Trastuzumab-containing adjuvant therapy should be used in women with node-positive, her2/neu-overexpressing breast cancers, and in women with node-negative breast cancer with a tumour larger than 1 cm and her2/neu overexpression. Here, ERBB2 is linked to breast cancer.